Gilead Sciences, Inc.

Xiaoning C Sheng

Choung U Kim

Aesop Cho

Qiaoyin Wu

Hyung-Jung Pyun

Michael O'Neil Hanrahan Clarke

John O Link

Edward Doerffler

Anthony Casarez

Kleem Chaudhary

Maria Fardis

Michael O Clarke

Jianying Wang

Hyungjung Pyun

Mingzhe Ji

Zhenhong R Cai

Melissa Fleury

Darren J McMurtrie

The present application includes novel inhibitors of HCV, compositions containing such compounds, therapeutic methods that include the administration of such compounds.

Antiviral compounds

The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

The invention is related to anti-viral phosphinate compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

Antiviral phosphinate compounds

The invention is related to a method of treating disorders associated with hepatitis C by administering to an individual a pharmaceutical composition which comprises a therapeutically effective amount of an anti-viral phosphinate compound.

The invention is related to phosphorus substituted anti-viral inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

Growing community of inventors

Foster City, CA, United States of America

Xiaoning C Sheng